A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer

Biochem Biophys Res Commun. 2021 Jan 22:537:78-84. doi: 10.1016/j.bbrc.2020.12.043. Epub 2020 Dec 30.

Abstract

The prostate cancer (PCa) poses serious threat to men's health. The androgen receptor (AR) is essential for normal prostate development and prostate cancer progression. We identified a novel lncRNA PCLN16 which is significantly correlated with AR signaling during prostate cancer progression. The AR-regulated PCLN16 was abundantly overexpressed in localized or metastatic prostate cancer tissues and AR-dependent cell lines. PCLN16 silence suppressed AR signaling and tumor growth. PCLN16 interacted with Huntingtin interacting protein 1 (HIP1) transcript to reduce HIP1 degradation. Therefore, PCLN16 could augment AR signaling via a novel positive feedback loop. Our experiments support an oncogenic role for PCLN16 and suggest that PCLN16 might serve as a potential target for therapeutic intervention.

Keywords: HIP1; LncRNA; PCLN16; Prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Cell Line, Tumor
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Gene Silencing
  • Humans
  • Male
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • RNA Stability / genetics
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / metabolism*
  • Receptors, Androgen / genetics*
  • Receptors, Androgen / metabolism
  • Signal Transduction*
  • Xenograft Model Antitumor Assays

Substances

  • AR protein, human
  • DNA-Binding Proteins
  • HIP1 protein, human
  • RNA, Long Noncoding
  • Receptors, Androgen